Search Results

Your search for Matthew J. Ellis, MD matches 3 pages

Showing 1 - 3

By Matthew J. Ellis, MD / 2014 San Antonio Breast Cancer Symposium

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."

breast cancer

By Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD / 2014 San Antonio Breast Cancer Symposium

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistant estrogen receptor-positive breast cancer.

breast cancer

By Matthew Stenger / Thursday, September 24, 2015 1:06 PM

Phase II Study Suggests Survival Benefit With First-Line Fulvestrant vs Anastrozole in Advanced Breast Cancer

Overall survival data from a phase II study, reported in the Journal of Clinical Oncology by Ellis et al, suggest a benefit of first-line fulvestrant (Faslodex) vs anastrozole in postmenopausal women with estrogen receptor–positive advanced breast cancer. The study protocol was amended to...

Apr

Today In Oncology

Search Results

Your search for Matthew J. Ellis, MD matches 3 pages

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Phase II Study Suggests Survival Benefit With First-Line Fulvestrant vs Anastrozole in Advanced Breast Cancer

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer